Author:
Hernandez W,Gamazon E R,Aquino-Michaels K,Patel S,O'Brien T J,Harralson A F,Kittles R A,Barbour A,Tuck M,McIntosh S D,Douglas J N,Nicolae D,Cavallari L H,Perera M A
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine
Reference41 articles.
1. IMS Institute for Healthcare Informatics. The Use of Medicines in the United States, Review of 2011, Parsippany, NJ; www.theimsinstitute.org .
2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.
4. Harper P, Young L, Merriman E . Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366: 864–866.
5. Cheng CM, McCurdy MR, Wong HA, Kayser SR . Pros and cons of dabigatran. Am J Health Syst Pharm 2011; 68: 1495.
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献